An abstract showing tumor specific targeting at all known tumor sites in glioblastoma patients, with no normal tissue uptake of ifabotuzumab, from a Phase 1 study will be presented at EANM'21
Humanigen Announces Completion of Enrollment in Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme BURLINGAME, Calif. (Business Wire) Humanigen, Inc.
(NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases,
today announced completing enrollment in its Phase 1 bioimaging study of ifabotuzumab in patients with recurrent glioblastoma multiforme (GBM). Ifabotuzumab, or ifab, is the Company’s proprietary anti-EphA3 monoclonal antibody. This trial is supported by funding from the Cure Brain Cancer Foundation. Results from the study, being conducted at the Olivia Newton-John Cancer Research Institute in Heidelberg, Victoria, Australia, are expected in the first half of 2021.
Humanigen Announces Completion of Enrollment in Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme
BURLINGAME, Calif. (BUSINESS WIRE) Humanigen, Inc.
(NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases,
today announced completing enrollment in its Phase 1 bioimaging study of ifabotuzumab in patients with recurrent glioblastoma multiforme (GBM). Ifabotuzumab, or ifab, is the Company’s proprietary anti-EphA3 monoclonal antibody. This trial is supported by funding from the Cure Brain Cancer Foundation. Results from the study, being conducted at the Olivia Newton-John Cancer Research Institute in Heidelberg, Victoria, Australia, are expected in the first half of 2021.
Humanigen Shares Rise on Completing Phase 1 Brain Cancer Trial Enrollment Source:
Streetwise Reports (12/17/20) Shares of Humanigen Inc. traded 24% higher after the company reported that it had successfully completed enrollment of patients in a Phase 1 Study of ifabotuzumab in glioblastoma multiforme.
Clinical stage biopharmaceutical company Humanigen Inc. (HGEN:NASDAQ), which is focused on developing therapies for treating cancer and infectious diseases, today announced that it is completing enrollment in its Phase 1 bioimaging study of ifabotuzumab in patients with recurrent glioblastoma multiforme (GBM).
The firm explained that its proprietary ifabotuzumab is an anti-EphA3 monoclonal antibody. Humanigan noted that it has received funding for the study from the Cure Brain Cancer Foundation and that the trial is being conducted at the Olivia Newton-John Cancer Research Institute in Heidelberg, Victoria, Australia. The company stated that it expects to